News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Wellstat Therapeutics Corporation Grants U.S. Distribution Rights to its Investigational Antidote for 5-FU Overexposure to Specialist Healthcare Company BTG plc (BGC.L)



7/6/2011 11:07:40 AM

GAITHERSBURG, Md.--(BUSINESS WIRE)--Wellstat Therapeutics Corporation announced today that it has granted U.S. marketing rights for the company’s investigational drug uridine triacetate to the specialist healthcare company BTG International Inc. for use as a potential treatment for accidental overexposure to the chemotherapy drug fluorouracil (5-FU) due to dosing errors or impaired clearance of 5-FU from the body. Wellstat has retained commercialization rights for treatment of 5-FU overexposure outside of the U.S. and for all other potential uses of uridine triacetate.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES